Impact of overactive bladder on women in the United States: Results of a national survey

Current Medical Research and Opinion

Volumn 23, Issue 1, 2007, Pages 65-76

  Dmochowski, Roger R ^a   Newman, Diane K ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anticholinergic agents; Overactive bladder; Quality of life; Urinary incontinence

Indexed keywords

OXYBUTYNIN; TOLTERODINE;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; ATTITUDE TO HEALTH; BACKACHE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG RELEASE; FAMILY RELATION; FATIGUE; FEMALE; HEADACHE; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; INCOME; LOOSE FECES; MAJOR CLINICAL STUDY; OCCUPATION; OVERACTIVE BLADDER; PATIENT SATISFACTION; PRESCRIPTION; QUALITY OF LIFE; QUESTIONNAIRE; SELF ESTEEM; SEXUALITY; STOMACH DISCOMFORT; UNITED STATES; VISUAL DISORDER; XEROSIS;

ADULT; AGED; CHOLINERGIC ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; UNITED STATES; URINARY BLADDER, OVERACTIVE;

EID: 33846705487     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X159533     Document Type: Article

References (50)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49
2. Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care 2000;6(Suppl 11):S565-S572
3. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 2001;87:760-6
4. Nygaard IE, Lemke JH. Urinary incontinence in rural older women: prevalence, incidence and remission. J Am Geriatr Soc 1996;44:1049-54
5. Samuelsson E, Victor A, Tibblin G. A population study of urinary incontinence and nocturia among women aged 20-59 years: prevalence, well-being and wish for treatment. Acta Obstet Gynecol Scand 1997;76:74-80
6. Stewart WF, Van Rooyan JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
7. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002;60(Suppl 1):7-12
8. Brown JS. Epidemiology and changing demographics of overactive bladder: a focus on the postmenopausal woman. Geriatrics 2002;57(Suppl 1):6-12
9. Shah D, Badlani G. Treatment of overactive bladder and incontinence in the elderly. Rev Urol 2002;4(Suppl 4):s38-s43
10. Ouslander JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology 2002;60:50-5
11. DuBeau CE. Interpreting the effect of common medical conditions on voiding dysfunction in the elderly. Urol Clin North Am 1996;23:11-8
12. Brown JS, Seeley DG, Fong J, et al. Urinary incontinence in older women: who is at risk? Obstet Gynecol 1996;87:715-21
13. Freeman RM, McPherson FM, Baxby K. Psychological features of women with idiopathic detrusor instability. Urol Int 1985;40:257-9
14. Yarnell JW, Voyle GJ, Sweetnam PM, et al. Factors associated with urinary incontinence in women. J Epidemiol Community Health 1982;36:58-63
15. Sampselle CM, Wyman JF, Thomas KK, et al. Continence for women: a test of AWHONN's evidence-based protocol in clinical practice [Association of Women's Health Obstetric and Neonatal Nurses]. J Obstet Gynecol Neonatal Nurs 2000;29:18-26
16. Lam GW, Foldspang A, Elving LB, Mommsen S. Social context, social abstention, and problem recognition correlated with adult female urinary incontinence. Dan Med Bull 1992;39:565-70
17. Smoger SH, Felice TL, Kloecker GH. Urinary incontinence among male veterans receiving care in primary care clinics. Ann Intern Med 2000;132:547-51
18. Van Oyen H, Van Oyen P. Urinary incontinence in Belgium: prevalence, correlates and psychosocial consequences. Acta Clin Belg 2002;57:207-18
19. Bogner HR, Gallo JJ, Sammel MD, et al. Urinary incontinence and psychological distress in community-dwelling older adults. J Am Geriatr Soc 2002;50:489-95
20. Kinchen KS, Burgio K, Diokno A, et al. Factors associated with women's decisions to seek treatment for urinary incontinence. J Women's Health 2003;12:687-98
21. Ricci JA, Baggish JS, Hunt TL, et al. Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther 2001;23:1245-59
22. Palmer MH, Fitzgerald S. Urinary incontinence in working women: a comparison study. J Women's Health 2002;11:879-88
23. Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. Br J Urol Int 2005;95:81-5
24. Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7:455-63
25. Lucente V, Goldberg R, Davila GW, et al. Impact of transdermal oxybutynin on the quality of life in OAB patients: results from the MATRIX study. Poster presented at: American College of Obstetricians and Gynecologists (ACOG) 54th Annual Clinical Meeting; May 6-10, 2006; Washington, DC
26. Avery K, Donovan J, Peters TJ, et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004;23:322-30
27. Hing E, Poe G, Euller R. The effect of methodological differences in two surveys' estimates of the percentage of employers sponsoring health insurance. Inquiry 1999;36:212-20
28. Whitmore RW, Byron MZ, Clayton CA, et al. Sampling design, response rates, and analysis weights for the National Human Exposure Assessment Survey (NHEXAS) in EPA region 5. J Expo Anal Environ Epidemiol 1999;9:369-80
29. Sandman D, Trauring A. Survey of adult women with overactive bladder. New York (NY): Harris Interactive Inc; January 2003
30. Finkelstein MM. Medical conditions, medications, and urinary incontinence: analysis of a population-based survey. Can Fam Physician 2002;48:96-101
31. Buchsbaum GM, Chin M, Glantz C, Guzick D. Prevalence of urinary incontinence and associated risk factors in a cohort of nuns. Obstet Gynecol 2002;100:226-9
32. Hannestad YS, Rortveit G, Hunskaar S. Help-seeking and associated factors in female urinary incontinence [The Norwegian EPINCONT Study: Epidemiology of Incontinence in the County of Nord-Trondelag]. Scand J Prim Health Care 2002;20:102-7
33. MacKay K, Hemmett L. Needs assessment of women with urinary incontinence in a district health authority. Br J Gen Pract 2001;51:801-4
34. Wenger NS, Solomon DH, Roth CP, et al. The quality of medical care provided to vulnerable community-dwelling older patients. Ann Intern Med 2003;139:740-7
35. Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br Med J 2003;326:841-4
36. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95
37. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10
38. Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001;185:56-61
39. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001;76:358-63
40. Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000;20:470-5
41. Dmochowski R, Kell S, Staskin D. Oxybutynin chloride: alterations in drug delivery and improved therapeutic index. Expert Opin Pharmacother 2002;3:443-54
42. Gupta SK, Sathyan G, Lindemulder EA, et al. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin Pharmacol Ther 1999;65:672-84
43. Kershen RT, Hsieh M. Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine. Curr Urol Rep 2004;5:359-67
44. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence: OROS oxybutynin study group. J Urol 1999;161:1809-12
45. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005;23:263-70
46. Murray M, Swan AV, Kiryluk S, Clarke GC. The Hawthorne effect in the measurement of adolescent smoking. J Epidemiol Community Health 1988;42:304-6
47. Siracusano S, Pregazzi R, d'Aloia G, et al. Prevalence of urinary incontinence in young and middle-aged women in an Italian urban area. Eur J Obstet Gynecol Reprod Biol 2003;107:201-14
48. Peyrat L, Haillot O, Bruyere F, et al. Prevalence and risk factors of urinary incontinence in young women. Prog Urol 2002;12:52-9
49. Dallosso HM, McGrother CW, Matthews RJ, et al. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. Br J Urol Int 2003;92:69-77
50. Dmochowski RR, Parker RL, Melkonian R. Effects of prior therapy on health-related quality of life following treatment with transdermal oxybutynin. Poster presented at: American Urogynecologic Society 27th Annual Scientific Meeting; October 19-21, 2006; Palm Springs, California